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‘… seeing an analogy where no one saw one before’ 
(Arthur Koestler, The Act of Creation, p. 175) 
 
Abstract:   
Safety and efficacy are two major aspects in assessing worth of a new health intervention. Statisticians 
tend to emphasize inference on efficacy. In comparison, inference on safety receives less attention. This is 
mainly because of complexity of safety data. This complexity level is comparable to that in biodiversity 
data in ecology. We draw analogy from biodiversity literature to summarize adverse event (AE) data. This 
article proposes an index named ‘adversity index’ (AdX for short), which combines data on all adverse 
events encountered in a clinical trial and not just the ones of ‘special interest’. In this sense the approach is 
inclusive. In ecology this index is known as ‘Shannon- Wiener’ diversity index. AdX follows asymptotic 
normal distribution which permits use of standard statistical tests for treatment comparisons. AdX is a 
simple measure of risk quantification, which is lacking in current literature. This single number summary 
is shown to facilitate safety profile comparison of treatments, overall as well as by subgroups. Further, it is 
shown how the index can be used for decision making by interim review committees like DSMB/DMC 
who find it difficult to take a go/ no-go decision in a short time span. Regulators can use AdX as a 
quantitative measure of risk while assessing benefit risk balance. This approach can sometimes lead to 
results that would have been missed without it. These ideas are illustrated using anonymized data on Phase 
III clinical trials conducted by major pharmaceutical companies; two on breast cancer and two on 
diabetes.  
Keywords: Drug safety, adverse event data, safety comparison by sub-groups, benefit risk 
assessment, assisting DSMB/DMC 
 
1. Introduction:   
Safety and efficacy are two major parameters in assessing the worth of a new health intervention. 
‘Drug approval decisions are based on a comprehensive assessment of the benefits of the drug and its 
known and potential risks’ 1. Statisticians tend to focus more on inference regarding efficacy than safety. 
Current practice of inference on safety is mainly based on adverse events of special interest, generally a 
tiny fraction of total AE types recorded while remaining bulk of adverse events are reported only as counts 
and percentages.  This article proposes an index named ‘adversity index’ (AdX), which represents 
integration of data on all adverse events encountered in a clinical trial.  Here we demonstrate that this 
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single value summary facilitates the safety profile comparison of treatments, at an overall and subgroup 
level. Further, we illustrate the potential use of this index by the Data Safety Monitoring Board at the time 
of interim review. In addition, the index can serve as a simple measure of overall risk, which is lacking in 
the current literature and can be used by the regulators while assessing benefit risk balance. AdX based 
analysis can sometimes reveal results that would not have been noticed with conventional approach. The 
proposed approach uses AE data more intensively than current methods; however, it is not meant to 
replace but supplement the conventional method of focusing on events of special interest. If a treatment is 
judged to be unsafe and unacceptable based on rates of occurrence of these events (as in case of 
Thalidomide or Vioxx) other adverse events may not play a role in decision making. Proposed approach 
will play a useful role in all clinical trials excluding such cases.  
2. Outline of the paper:  
Section three provides motivation of the paper. It describes current practice of safety data reporting in 
clinical trials and points out its limitations.  It draws analogy between complexity of adverse event (AE) 
data in clinical trials and biodiversity data in ecology. Using this analogy, an index of biodiversity is 
proposed as a summary measure of AE data. Interpretation of and statistical inference on this summary 
measure are explained. Various uses of this index are illustrated in section four through analysis of Phase 
III clinical trials conducted by pharmaceutical companies.   
3. Safety Data Analysis: Current scenario and proposed modification 
3.1 Goals of safety data analysis: 
In a typical clinical trial, an individual adverse event (AE) is noted immediately and acted upon as 
necessary.  Collectively, safety data are examined at multiple stages: (a) by the DSMB/DMC during 
interim review of the trial to judge whether safety concerns are serious enough to warrant stopping the 
trial, (b) by the sponsors at the end of the trial to prepare clinical study report (CSR) following ICH E3 
guidelines, and (c) by the regulators for benefit risk assessment prior to decision on drug approval.   
3.2 Limitations of current practice: 
In stage (a), a statistician providing data to a DSMB/DMC faces a dilemma: reporting all the data from 
the case report forms may overwhelm the committee members; on the other hand, selective reporting may 
hamper the ability of the committee to make informed judgments about safety. Generally the committee is 
presented with bulky and undigested data. The task of interim review by the DSMB/ DMC is complicated 
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by the extremely limited time available to ‘wade through seemingly endless pages’2.  This situation 
warrants correction. The proposed approach offers one solution to this problem.   
In stage (b), the safety data analysis in a typical CSR is based on well-established statistical methods. 
The trial protocol often specifies certain adverse events (AE) being of ‘special interest’ in relation to 
disease condition and drug under study, called Tier 1 AEs
3
. Rates of occurrence of these events are 
compared across treatments using chi-square test, Fisher’s exact test etc. Sometimes in literature we come 
across analysis of Tier 2 events as well, similar to analysis of Tier 1 events.  In either case the analysis is 
beset with the problem of multiple testing and false discovery rate (FDR)
4
.  Occasionally one encounters 
suggestions to use graphical tools to summarize safety data
5,6
. They do not seem to have a wide 
acceptance. In general, there is awareness that ‘Statistical methods for drug safety assessment are still 
evolving’ 7. Current methods fail to provide a cogent summary of the safety data. A typical CSR offers a 
‘safety data summary’ which runs into hundreds of tables, with each table possibly spanning across 
multiple pages. In a breast cancer trial by Eli Lilly (NCT00006459), the length of section 14.3, ‘Safety 
Data Summary’ of the CSR was more than 220 pages. Such a length contradicts the concept of summary. 
In case of the diabetes trial by Boehringer Ingelheim (NCT01159600) the safety tables span across more 
than 1800 pages. The absence of a clear and concise summary of safety data poses a challenge in weighing 
it against benefit. In place of this bulk what is really needed is a concise measure of overall safety (profile) 
of a treatment.   
At stage (C) regulators involved in benefit risk assessment also face a problem. Review of current 
benefit-risk literature reveals a common difficulty in quantifying overall risk.  As a result ‘There is no 
defined and agreed methodology to combine benefits and risks to allow direct comparisons.’ 8. 
In addition to the above three stages, a special situation requiring focussed safety data analysis may 
arise. Here is an illustration of such a situation: ‘Either before or after marketing approval, there is 
sometimes a need for a large randomized controlled safety study to evaluate a concern that may have 
arisen from observational adverse event reporting’ 9. The methods described below will also be applicable 
to such a situation.  
3.3 Root cause of weakness in current practice: 
Statistical methods for demonstrating efficacy of a new medicinal product are well developed. Why do 
methods for safety data analysis lag behind those for efficacy evaluation? In efficacy evaluation, the 
assessment is relatively straightforward because while developing a drug or a treatment, the researcher 
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knows precisely the type of benefit that the treatment should generate. For example, in case of an 
antihypertensive drug lowering of blood pressure is desired. Similarly, for anti diabetic drug lowering of 
blood sugar or for an oncology study, increase in median overall survival is desired. In addition to these 
primary end points, a relatively small set of co-primary or secondary efficacy end points may also be of 
interest. Thus the number of endpoints to be assessed for efficacy is limited, and the corresponding 
statistical methods for treatment comparison are well established.  
In contrast, when we consider the safety aspect of the drug in general and adverse events in particular, 
the complexity level is high: the number of distinct AEs (AE types) in a trial is large (several hundred), 
the severity/ seriousness levels of AEs are different, the same subject may experience multiple AEs, the 
same AE may affect many subjects, the same AE may affect the same subject repeatedly, AEs may be 
associated etc. Therefore, statisticians struggle to offer a meaningful summary. This could create a feeling 
of despondency when it comes to safety comparison of treatments, which is reflected in the following 
comment : ‘The FDA, industry and academia remain in a quandary as to how to respond in a responsible 
fashion to observed differences in reported frequencies of adverse events.’10. 
Sometimes, complications may arise in the analysis of efficacy data as well. The recent ICH E9 (R1) 
addendum discusses the difficulty of accommodating inter-current events.  It suggests strategies for 
developing estimands to handle such events. The current debate on estimands mainly revolves around 
efficacy evaluation. However, the concept is also applicable to safety endpoints and different safety 
estimands may be of interest.We see an opportunity for developing a new approach to summarising and 
reporting AE data using an estimand.  
3.4 Proposed solution based on analogy between safety data and biodiversity data:  
Since conventional methods do not seem to give satisfactory results, an unconventional line of attack 
may be productive. A similar situation may have been encountered in a completely different branch of 
science and a solution may have been found there. In such a case, drawing an analogy and borrowing 
relevant tools may be helpful. This is exactly what we propose to do.  
We draw an analogy between AE data and biodiversity data. The complexity of adverse event (AE) 
data in a typical clinical trial is comparable to the complexity of biodiversity data. In ecology, the 
measurement of biodiversity is a major topic of interest. Biodiversity broadly means variability in life 
forms. In a typical ecosystem, e.g. a tropical forest, many types of organisms coexist. These organisms 
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include trees, insects, mammals, birds etc. They vary in numbers, types and other parameters. Ecologists 
are interested in quantifying this variability. Let us consider only birds. Ecologists study birds in a forest 
through a sample survey of the field by recording the bird species encountered and their count 
(abundance). This information forms the basic data set. In a tropical forest, the list of bird species can be 
very long (in hundreds) and the counts can range from one individual to several thousand individuals. The 
tool used by ecologists to summarise this variation is the so called ‘index of diversity’. A forest with a 
higher index of diversity is considered to be richer. Diversity can be assessed at different taxonomic levels 
(species, genus, family etc.). 
The basic data for the measurement of species diversity is a list of species along with the 
corresponding abundances.  The parallel for clinical trials is a list of AE types along with the 
corresponding frequencies of occurrence in a trial. These AE data represent the safety profile of a 
treatment. This parallel suggested a possible deeper analogy.  Table 1 specifies the other components in 
the analogy between AE data and biodiversity data. 
Table 1: Analogy between biodiversity data and AE data 
Biodiversity Data Adverse Event Data 
Field Survey Clinical trial or a set of clinical trials (ISS) 
Species AE type 
Species Abundance Frequency of occurrence of an AE type 
Group of Species AEs by SOC/ any appropriate group 
Sampling effort # Patients / patient days  in a trial 
Species turnover 
(α, β, γ diversity) 
AE turnover across treatments 
(intersection sets) 
Taxonomic hierarchy MedDRA hierarchy 
 
This remarkable similarity between the two domains has prompted us to explore the possible use of 
summary measures from ecology for AE data in clinical trials. Ecologists use not one but many diversity 
indices. All these indices are based on the number of species (say K) and their relative abundances  
(pi, i= 1 to K, ∑pi =1). Two of these indices are well known in ecology literature: Shannon- Wiener index 
(SW) and Simpson’s index (SI). The SW index is our choice. This index originated in thermodynamics 
and was later adopted in other branches of science such as chemistry, biology, linguistics etc. often under 
the name ‘Entropy’. A relevant example is its very recent use in the anonymization of clinical trial 
reports
11
. Here uncertainty of re-identification of ‘protected personal information’ (PPI) is important.  SW 
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index captures this uncertainty. Greater the value of index, greater is the uncertainty. The formula for the 
Shannon-Wiener index is  
SW= -∑ pi* ln(pi)     Eq.1  
where pi is the relative abundance of the i
th
 species and the sum is over all species. Higher value of the 
index indicating greater randomness or greater ‘disorder’ represents a ‘richer’ ecosystem. The value of 
index depends on two factors: first, larger number of species leads to larger value of index; second, for a 
given number of species, evenness in abundance across species results in a higher value of the index. To 
understand the effect of evenness on the index, consider a hypothetical case of three communities for 
comparison; each of the three communities, has five species (K= 5) with a total of 100 individuals 
(N=100). The abundances of individual species and the resulting diversity indices are shown in Table 2.  
 
Table 2: Species-wise abundances in three hypothetical communities and their 
diversity indices 
 
Community Species Index 
SW 
Comment 
S1 S2 S3 S4 S5 
1 1 1 1 1 96 0.22 Extreme unevenness 
2 1 3 6 10 80 0.73 Intermediate evenness 
3 20 20 20 20 20 1.61 Extreme evenness 
 
In the first community four species are represented by only one individual each, and the fifth species 
has 96 individuals. The second community has more than one individual in some species. In the third 
community each of the five species is represented by 20 individuals. The diversity index has the smallest 
value for the first community, the largest value for the third community, and an intermediate value for the 
second community.  
3.5 Definition and interpretation of adversity index:  
The central proposal of this paper is that AE data in a clinical trial should be summarised using the 
Shannon Wiener (SW) index defined in Eq. 1. Let us suppose that there are K AE types, with a total 
number of episodes N and the relative frequency of occurrence of i
th  
 AE type denoted by pi.  These data 
can be summarised using Eq. 1 and we name the resulting value as ‘Adversity Index’, AdX for short. As 
stated in section 3.4, the AdX value will increase as K increases. Further, the AdX value will increase if pi 
values are similar across AE types. It may be useful to emphasize that the index is based on counts of AE 
episodes and not on the number of subjects affected.  Further it should be kept in mind that, like any 
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summary measure or index, AdX suppresses many details of the data. Equality of AdX for two data sets 
does not imply identical profiles. However, this summarization facilitates comparison of treatments. Use 
of AdX is intended to draw attention to a treatment with more AE types and their relative abundance. It is 
not intended to identify individual types of AE’s or rare AE’s.   
Conventional approach to safety data analysis makes a distinction between levels of seriousness, 
grades of severity, different body systems etc.  So far we have not incorporated these distinctions in AdX. 
However, when interest is focussed on a subgroup (by age/ gender/ SOC/ seriousness/ severity etc.) index 
can be calculated for that subgroup. Once a subgroup shows significant treatment difference in AdX, then 
additional exploratory analyses and/or more careful perusal of the types of AEs are likely needed to 
explain the AdX difference.  A common terminology in literature is Tier 1/Tier 2-3 events. This is yet 
another way of sub grouping. Current practice is to compare rates of individual Tier 1 AEs across 
treatments. Tier 2-3 events are reported as counts and percentages. AdX analysis can also be carried out 
for one or more of these subgroups as needed.  
In the ecological context, a higher value of SW is desirable. Is this true for AdX also? We contend that 
the opposite is true. If there is only one AE type, value of AdX is zero. This zero value does not indicate 
absence of risk. It simply indicates that we know precisely where to focus the risk mitigation efforts. As 
the possible number of AE types increases and the AdX value increases, the challenge in preparing for all 
eventualities becomes more daunting. Secondly, if the number of AE types is the same for two treatments, 
a higher AdX implies a greater evenness in counts of AE occurrence across AE types. This scenario 
indicates greater uncertainty about which AE type will affect the subjects.  As a consequence the risk 
mitigation effort will need to pay attention to many more AE types, which is an undesirable situation. 
Hence we regard higher value of the index as an indication of lower safety level.  
3.6 Inference on AdX and safety comparison of treatments: 
A key question of interest for sponsors or regulators is which of the treatments is better in overall 
safety. The simplest answer is that the treatment with a lower value of AdX is safer. The next essential 
question is whether the difference in AdX is statistically significant or due to chance alone. To answer this 
question, we have to consider the distributional properties of AdX such as standard error and confidence 
interval. Here, it is perhaps relevant to make a distinction between a true and unknown population AdX 
(PAdX) and the estimate from sample data. Consider a target population of patients with a specific disease 
condition (say breast cancer) treated with a specific drug (say Gemcitabine by Eli Lilly). Collection of 
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possible adverse events in cancer patients getting this treatment is the universe of interest. The adversity 
index based on this set and associated probability vector is PAdX (an estimand for safety). In a particular 
clinical trial we get a sample of these adverse events and we calculate a sample AdX.  This is the estimate 
of PAdX. For convenience, we will drop the prefix P from now on. The context will make it clear whether 
we are discussing sample AdX or unknown population AdX.  If the sampling distribution of AdX is bell-
shaped, statistical methods based on normal distribution can be used. AdX follows an asymptotic normal 
distribution
12
 with mean PAdX and variance 
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where N is the total number of AE episodes, K is the number of AE types and pi is the proportion of 
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4. Application of Adversity Index to data in clinical trials: 
4.1 Summary and AdX of AE data:  
The remainder of this paper illustrates the use of AdX for comparing the safety profiles of treatments 
in four clinical trials (coded in text as EL, BI, RO and GSK). Table 3 gives the details of these trials.  
Table 3: Data Source (Anonymized) 
Serial 
Number NCT  Sponsor Indication  Code used in text 
1 NCT00006459 Eli Lilly Breast cancer EL 
2 NCT01159600 Boehringer Ingelheim Diabetes Mellitus Type II BI 
3 NCT00333775 Roche Breast cancer RO 
4 NCT01128894 GlaxoSmithKline Diabetes Mellitus Type II GSK 
All 4 trials are Phase III. Data were made available by https://www.clinicalstudydatarequest.com 
 
As discussed in section 3.2 the summary provided in a typical CSR is not concise and is often difficult 
to comprehend or interpret. Our attempt is to offer a better alternative. Table 4 shows a high level 
summary of the various counts related to safety for all four clinical trials analysed. 
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Table 4: High-level summary of four trials 
 Study 
EL BI
@
 RO GSK 
Therapeutic Area: Breast Cancer DM II 
(Met) 
DM II 
(Met + SU) 
Breast Cancer DM II 
# Subjects 521 718 786 736 812 
# AE episodes 55,803 1052 1655 17448 3416 
# AE types 208 325  384 862 549 
# Subjects with at least one AE (%) 521 (100.0) 426(59.3) 541(68.8) 728(98.9) 667(82.1) 
# Treatment arms 2 4 4 3 2 
Test drug Gemcitabine Empagliflozin Bevacizumab Albiglutide 
@ The BI trial had two sub-studies based on the background therapy (i) Metformin (Met) and  
(ii) Metformin + sulphonylurea (Met+SU) 
 
We note in passing that (i) the number of AE episodes in oncology trials is far greater than in diabetes 
trials, (ii) within oncology, the count of AE types in RO trial is over four times the count in EL trial even 
though the count of AE episodes is less than a third.  
Table 5 shows our first attempt at creating an overview of the AE data for the EL study. Here we 
observe that all the subjects in the EL trial experienced at least one AE. Total number of AE episodes in 
the GT group is 21% greater than that in the T group. The number of distinct AEs is slightly greater in the 
GT group than in the T group.  
Table 5: Summary of AE data by treatment (EL) 
Variable Treatment
†
 Total 
GT T 
# subjects 262 259 521 
# AE episodes 30446 25357 55803 
# distinct AEs 187 178 208 
# subjects with at least one AE(%) 262(100%) 259(100%) 521(100%) 
AdX 3.64 3.48  
SE(AdX) 0.0079 0.0086  
Difference (AdXGT-AdXT) and SE 0.16(0.0117)  
Data Source: NCT00006459; Sponsor Name: Eli Lilly;  
Indication: Breast Cancer. 
† 
GT= Gemcitabine + Paclitaxel; T= Paclitaxel. 
 
While the above summary appears concise and relevant, many clinical trials have features which 
require a more detailed table. The EL trial on breast cancer naturally involves only one gender. In general, 
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there may be interest in gender-wise comparison of response to treatments. Other features of interest can 
be age, background therapy etc. An appropriately modified version of the above table can be used.  
Turning to inference, the Z-statistic for comparison of AdX for two treatments in the EL trial is 
0.16/0.0117= 13.67, which is statistically significant at every reasonable choice of (α); level of 
significance. We note that standard errors of AdX for both treatments and their difference are very small 
because of large values of N1 (30446) and N2 (25357). Thus, with large counts of AE episodes, the 
sample AdX values are essentially the population values. Such large number of AE episodes may not be a 
common occurrence. To see results for a case with moderate number of AE episodes we consider the BI 
trial. It had four treatment arms compared separately in two sub-studies (by background therapy). Table 
6A shows AdX values for each gender, sub study and treatment. Table 6B gives p-values for treatment 
comparison within each gender and sub study.  
Table 6A: AdX and SE by treatment and gender (BI) 
Background Therapy Gender 
Treatment arm 
10 mg 25 mg Placebo (P) Open 25 mg 
Metformin           
Female 
4.38 
(0.0654) 
4.25 
(0.0657) 
3.97 
(0.0793) 
3.02 
(0.0921) 
Male   
4.07 
(0.0859) 
4.25 
(0.0704) 
4.32 
(0.0696) 
3.63 
(0.0591) 
Metformin + SU      
Female 
4.04 
(0.0836) 
4.01 
(0.0912) 
4.05 
(0.0732) 
3.66 
(0.0861) 
Male   
4.08 
(0.0993) 
3.69 
(0.1116) 
4.16 
(0.0806) 
3.84 
(0.0836) 
Data Source: NCT01159600; Sponsor Name: Boehringer Ingelheim (BI); Indication: Diabetes Mellitus Type II. 
 
Table 6B: p-values for Comparison of treatments within each sub study (BI) 
Sub Study  Gender 10 mg - P 25 mg -P 25mg (Open) –P (Blinded –open) 25 mg 
Met Females <0.001 <0.003 <0.001 <0.001 
Males 0.012 0.240 <0.001 <0.001 
Met + SU Females 0.46 0.36 <0.001 0.003 
Males 0.266 <0.001 0.003 0.141 
Data Source: NCT01159600; Sponsor Name: Boehringer Ingelheim (BI); Indication: Diabetes Mellitus Type II. 
 
Notice that 5 out of the 16 comparisons fail to attain significance. Remaining 11 comparisons yield 
low p-values. It is generally expected that higher dose is accompanied by higher toxicity. So AdX for 25 
mg should be higher than that for placebo. In fact in case of males with metformin as background therapy, 
AdX for 25 mg is comparable to placebo. Even more surprising is the case of males with Met + SU as 
background therapy where AdX for 25mg dose is significantly smaller than placebo, indicating better 
safety. The corresponding picture in females is exactly the opposite. Such subtle features seem to be 
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missed out in conventional analysis in CSR. Here is what CSR reports: ‘Overall empagliflozin treatment 
was generally well tolerated and showed similar safety profile compared to placebo in patients with 
Metformin only and Metformin plus sulphonylurea  background medications (CSR p. 19)’.  
4.2 Clinical significance of AdX differences: 
In clinical trials it is prudent to check the clinical significance along with the statistical significance. 
How can the clinical significance of difference in AdX be judged? AdX is only an index; therefore its 
absolute value is hard to interpret. Ecologists have faced the same difficulty. Hence it is relevant to 
examine their approach. Ecologists use a concept called ‘effective number of species’. Analogously we 
will introduce the concept of Effective Adversity Load Score (EALS). EALS is a transformation of AdX.  
We explain the concept of EALS with an example (Table 7). Consider two treatment arms. In the first 
arm, there are four AE types (K=4), with the corresponding frequencies of occurrence shown in column  
N1i. In the second arm, there are two AE types (K* =2). In both cases, the AdX value is the same, viz.0.69. 
Therefore, the two safety profiles are similar (in terms of AdX). The main difference is that in Arm 2 both 
AEs occur with equal frequency. The second arm is synthetic and is not expected to be encountered in 
reality. However, there is a mathematical relationship between K* and AdX. The value 2 is equal to exp 
(0.69). Therefore, the Effective Adversity Load Score (EALS) for Arm one is 2. 
Table 7: Example data with EALS =2 
 Arm 1 Arm2 
AE type N1i P1i N2i P2i 
AE1 81 0.81 50 0.50 
AE2 7 0.07 50 0.50 
AE3 6 0.06 0 0.00 
AE4 6 0.06 0 0.00 
Total 100 1.00 100 1.00 
AdX  0.69  0.69 
 
In general the formula K* = exp (AdX) may not yield an integer value. Thus, it need not represent any 
real treatment. K* is a mathematical characterization of AdX. If K* happens to be an integer, we can 
imagine a hypothetical treatment with K* AE types each occurring with the same frequency. To phrase it 
differently, a treatment with K AE types with unequal frequencies of occurrence is in effect equivalent to 
another (hypothetical) treatment with K* AE types each with the same frequency of occurrence. The 
safety profile of a treatment can be represented either by AdX, or, equivalently, by K*, which we call 
EALS. We believe that the difference in EALS value may be easier for clinical interpretation. 
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For the EL trial, let us use the AdX values in Table 5 to calculate the EALS. Here, EALS (T) =32 and 
EALS (GT) = 38 (values rounded). The difference [AdX (GT) – AdX (T)] = 3.64-3.48 = 0.16 translates 
into increment of six equally frequent AE types.  For the BI trial (Table 6A) consider the 25 mg and 
placebo groups for males of the Met + SU sub-study. The EALS for placebo is [exp( 4.16)] =64 and that 
for 25 mg is [(exp(3.69)]= 40.  Thus, the safety profile of 25 mg group is as if subjects experienced 24 
fewer (effective) number of AE types compared to subjects in placebo group. Perhaps clinicians can relate 
more easily to this type of statement. 
4.3 Normalisation of AdX:  
The above approach is suitable for comparing treatments when the number of AE types recorded in 
two treatments is similar. In some special scenarios (as illustrated below) when this is not so, a further 
normalization becomes necessary. In such cases, if AdX values are different, a comparison of EALS 
values is not sufficient. Hence we divide each EALS value by the corresponding value of K, observed 
number of AE types. We call this value Standardised EALS or SEALS (=K*/K). Note that K* is always 
less than K; therefore, the value of SEALS will always be between 0 and 1. A value of 1 indicates K* = K, 
i.e. all AE types occur with roughly equal frequency in data. This scenario poses a challenge for safety 
risk management. In general, the smaller the value of SEALS, the easier is the safety risk management.   
Here is an example where the values of K are very different in two groups. In the BI study on Type II 
diabetes the same dose of 25 mg of empagliflozin is administered as a blinded arm to one group and as an 
open arm to another group.  
This feature of the BI trial can be considered as an experiment by itself. Blinding is an essential aspect 
of a clinical trial design. Regulators not only insist on blinding, but also demand an assessment of the 
success of blinding. This requirement is because of a clear recognition that successful blinding reduces the 
placebo effect and the possible bias in efficacy assessment. What is the impact of blinding on safety 
assessment? It is hard to find in literature any discussion about the relation between blinding and safety 
assessment. Further we do not often encounter the same treatment in a clinical trial under both blinded and 
open-label conditions. What we do encounter is an ‘open-label extension’ that follows a blinded trial but 
here ‘Analysis strategies need to be developed and implemented to provide unbiased estimates of safety 
and tolerability’13. 
By design in the BI trial, the open-label arm has considerably fewer subjects (about a third of blinded 
arm). When the number of subjects is smaller, rare events are easily missed. Hence the number of 
observed AE types is smaller for open arm. Table 8 shows the dilemma encountered and a solution.  
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Table 8:  AdX normalization by number of AE types (K) (BI Study) 
 
AdX(25 mg) EALS (K*: rounded) # AE types (K) SEALS (K*/K) 
1 2 3 4 5 6 7 8 9 
 
Blinded Open Blinded Open Blinded Open Blinded Open 
MetF 4.25 3.02 70 20 95 23 0.74 0.89 
MetM 4.25 3.63 70 38 92 41 0.76 0.92 
MSF 4.01 3.66 55 39 107 48 0.51 0.81 
MSM 3.69 3.84 40 47 105 60 0.38 0.78 
Data Source: NCT01159600; Sponsor Name: Boehringer Ingelheim (BI); Indication: Diabetes Mellitus Type II. 
 
 This trial consists of two sub-studies depending on the background medication (Metformin and 
Metformin + sulphonylurea). We get four groups because there are two background medications (Met/ 
MS)   and two genders (M/F). Columns 2 and 3 of Table 8 show that in three out of four cases the blinded 
arm has a higher AdX suggesting lower safety level. We transform these values to EALS values shown in 
columns 4 and 5. Here for the Metformin female group, the blinded arm has (70-20=) 50 additional 
effective AE types compared to the open-arm. This difference appears to be large. Columns 6 and 7 point 
out that the number of AE types in the blinded arm is much greater larger than the corresponding number 
in the open-arm. Therefore, further normalization is necessary. It is shown in columns 8 and 9.  
Remarkably, after normalization, the picture reverses. In all four groups, the SEALS value for the 
open arm is greater than that for corresponding value in blinded arm. It suggests that open arm is less safe 
than blinded arm. In conclusion the ranking based on AdX or EALS should be used only when the number 
of AE types is similar. Otherwise use of SEALS is recommended.  
4.4 Subgroup analysis: 
Protocols often provide for analysis of efficacy endpoints in subgroups by demographic factors, 
prognostic factors, prior treatment etc. Use of AdX allows us to carry out similar analysis for safety. An 
illustration of AdX by age groups for the RO trial is given in Table 9 which shows that the youngest and 
the oldest age groups respond differently than the intermediate age groups. In both the extreme age 
groups, the high dose has a significantly higher AdX value than the low dose or placebo.  
Perhaps there is awareness about safety issues in case of the age group ‘> 65’. It is reflected in various 
comments in the CSR.  For example ‘Some side effects are more common in elderly patients than in 
younger patients’.  (p. 874).  In addition to this general reference, specific adverse events are also 
mentioned. For example ‘overall increase in bleeding events’ (CSR p 737),   ‘increased risk of 
...CVAs/TIAs/ MIs’ (CSR p 379).  
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Table 9: AdX by age group and treatment (RO) 
 
Treatment 
Age group (Years) 
<40 40-50 50-65 >65 
AdX Doc 4.19 4.58 4.67 4.5 
 
7.5Bv 4.21 4.61 4.68 4.4 
 
15Bv 4.45 4.55 4.72 4.65 
p-value 
(Diff) 
7.5Bv-Doc > 0.05 > 0.05 > 0.05 > 0.05 
15Bv-Doc <0.001 > 0.05 > 0.05 <0.001 
15Bv-7.5Bv <0.001 > 0.05 > 0.05 <0.001 
Data Source: NCT00333775; Sponsor Name: Roche; Indication: Breast cancer. 
 
However, the suggestion in Table 9, that a high dose is less safe for the age group below 40 years 
appears to be new. It is brought out by use of AdX.  
This is not a unique instance. Next example shows subgroup difference in overall safety when CSR 
suggests otherwise. The CSR of  the BI trial gives the following comment on safety analysis: ‘Overall 
empagliflozin treatment was generally well tolerated and showed similar safety profile compared to 
placebo in patients with Metformin only and Metformin plus sulphonylurea  background medications’ 
(CSR p. 19). In contrast Table 6A suggests that there may be treatment differences. Consider the female 
group with Metformin as background medication. Here the AdX value for placebo (3.97) is less than 
either of active treatment arms (4.38 and 4.25). Further the differences are statistically significant (first 
row of Table 6B). Why was this difference missed out in CSR? Perhaps the explanation lies in the second 
row of Table 6A (for males). Here the AdX value for placebo (4.32) is greater than either of active 
treatment arms (4.07and 4.25). Further the difference between 10 mg and placebo is significant and active 
treatment is safer than placebo.  This is a reversal from the female group. Perhaps because CSR gives 
results for data pooled over genders, the opposing differences get averaged out. 
4.5 AdX by SOC:  
An AE episode is routinely classified by System Organ Class (SOC). Depending on the therapeutic 
area one or more specific SOCs may be of interest. For example the CSR of the EL trial on oncology 
states:  ‘As expected with chemotherapy, clinically significant laboratory toxicities were primarily 
hematologic’ (EL CSR p. 5).  Other therapeutic areas may have some other SOCs of primary interest. 
Therefore the safety comparison of treatments by SOC is useful.  Hence SOC wise AdX can potentially 
reveal more insights. We use the BI trial data to illustrate this possibility. Table 10A shows treatment 
comparison of AdX for each SOC separately. Last two columns give the p-values for comparison of active 
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treatment with placebo. The differences are significant in two cases; ‘Infection and infestations’ (10 mg 
Vs placebo) and ‘Metabolism and Nutrition’ (25 mg Vs Placebo). 
Table 10A: SOC wise comparison of AdX (BI-Metformin group) 
SOC 
Treatment (AdX and SE) p-value (diff) 
10 mg 25 mg Placebo 10mg-Placebo 25mg-Placebo 
GI 2.43(0.127) 2.37(0.157) 2.3(0.155) 0.258 0.375 
I & I 2.82(0.126) 2.44(0.130) 2.5(0.135) 0.042 0.626 
MAN 1.84(0.169) 2.11(0.132) 1.49(0.176) 0.076 0.002 
MS 2.32(0.104) 2.36(0.133) 2.44(0.136) 0.759 0.663 
CNS 2.04(0.199) 2.02(0.171) 1.71(0.246) 0.148 0.150 
Renal 1.68(0.163) 2.03(0.107) 1.89(0.201) 0.792 0.270 
Data Source: NCT01159600; Sponsor Name: Boehringer Ingelheim (BI); Indication: Diabetes Mellitus Type II. 
 
Table 10B: # AE episodes in MAN by treatment 
(BI-Metformin group) 
AE(total # types 15) 10 mg 25 mg Placebo 
Hyperglycaemia 6 2 23 
Hypoglycaemia 21 1 1 
Others  18 19 17 
AE with zero count 3 5 6 
Total 45 22 41 
Data Source: NCT01159600; Sponsor Name: Boehringer 
Ingelheim (BI); Indication: Diabetes Mellitus Type II. 
 
Next step is to look for individual AE types responsible for significant differences. Let us select SOC 
MAN (metabolism and nutrition), the case with lowest p-value. The results are in Table 10B. There were 
15 distinct AE types in this SOC. Out of these, 2 AE types have substantial counts in at least one treatment 
arm. Hyperglycaemia has the highest count in the placebo group while hypoglycaemia has the highest 
count in the 10 mg group. Identifying such specific events is precisely what a DSMB looks for. In this 
sense, SOC wise AdX analysis can be of assistance to DSMB. 
Again this is not a unique case. In the RO trial SOC wise comparison of treatments yields only one 
significant difference. It is for the SOC ‘Respiratory, thoracic and mediastinal disorders’.  Drilling down 
to individual AE types reveals that only one AE type stands out viz. Epistaxis. Here active treatment arms 
have much larger episode counts than placebo.   
4.6 Safety picture at interim looks:  
Above illustration is based on data at the end of the trial; but similar analysis is possible at interim 
looks as well. In addition to identification of individual AE types that discriminate between treatment 
arms, it is also possible to assess overall safety of test product relative to placebo at interim looks. AdX as 
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a measure of overall safety profile can be beneficial here because it is brief, cogent and inclusive. The 
question of interest is whether the picture of relative safety at interim look remains the same at the end of 
the trial. We shall use the data from completed trials to examine this question.  
The total trial duration can be divided into (say) three equal parts and the summary measure of choice 
such as the count of AE types, AdX etc. can be calculated at each stage. This is illustrated with data from 
the GSK trial.  Figure 1 shows AdX values at two interim and final time points, by gender and treatment.   
AdX value appears to increase gradually as the trial progresses. This behaviour can be mainly 
attributed to the increase in count of AE types observed. At two-third of the trial period, we observe more 
than 80% of the AE types. Further, the gender-wise AdX values appear to reveal an interesting pattern as 
seen in the Figure 1.  
 
In the case of males (dotted lines), the AdX value for Liraglutide (comparator) is higher than that for 
Albiglutide (GSK drug) throughout; however, no difference is statistically significant. On the other hand, 
in the case of females (continuous lines) ordering of treatments reverses. Albiglutide has a higher AdX 
than Liraglutide at every look.  Additionally, the difference is statistically significant every time. Thus, for 
females, the drug under investigation is less safe than the comparator.  This fact would have been detected 
at the first interim look itself (one-third of the trial period).  
These findings contradict the conclusion in CSR that ‘Results from this study suggest that albiglutide 
administered once weekly has a comparable efficacy and safety profile to an approved GLP-1 agonist .....’ 
(CSR p.147)
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. 
The above conclusion may be true for males but not for females. This shows how AdX value can be a 
useful guide to the DSMB in forming an opinion about the relative overall safety of different treatments at 
3.5 
3.7 
3.9 
4.1 
4.3 
4.5 
4.7 
F1/3 F2/3 F-Full M1/3 M2/3 M-Full 
A
d
X
 
Look 
Figure 1: AdX at interim looks by Gender (GSK) 
Albiglutide, Liraglutide 
Females 
Males 
18 
 
interim looks. It would also be relevant to check the extent to which such a guideline works for the other 
three trials.  
In the EL trial the AE onset dates were not available in a large number of AE episodes.  Hence the 
data could not be separated for interim looks. In the BI and RO trials, we observe a repetition of the 
suggested pattern i.e. the overall safety picture is reasonably clear at two-third of the trial.  
4.7 Analysis by exposure to drug: 
It appears that examination of safety by exposure can reveal interesting features of treatments. In 
oncology, exposure assessment is straightforward because the drug is administered sequentially in cycles 
and the number of cycles completed is a surrogate measure of exposure. The question of interest could be 
‘How does the AE profile in terms of AdX, number of AE types and number of AE episodes change with 
the number of chemotherapy cycles administered?’.  In Figures 2A, 2B, and 2C number of cycles is 
represented on the X axis and the AE summary measure is represented on the Y axis for the RO trial.  
We observe that the AdX values (Figure 2A) increase in the beginning but soon saturate. Here high 
dose has higher value of AdX throughout. The AdX curves for the other two arms overlap substantially. 
For the AE types (Figure 2B), although the picture is again of saturation, the placebo curve shows the 
lowest value throughout and the two active doses show higher values. The same holds for the number of 
episodes as well (Figure 2C).  Saturation in AdX and the number of AE types is expected. However, 
saturation in the number of episodes appears to be counter-intuitive. The episode count is expected to 
increase with number of cycles received.  The saturation is only in appearance; the cumulative count does 
not quite saturate but increases gently. The reason for gentle increase in count of episodes is that due to 
withdrawal or disease progression, the number of subjects declines sharply with increasing number of 
cycles. After about 15 cycles hardly any subjects are left (Figure 2D). The message from these graphs 
seems to be that picture of overall safety becomes clear after only about five or six cycles.  
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4.8 AdX with MedDRA Hierarchy:  
 
So far AdX was assumed to be calculated at preferred term level (PT). This is not necessary. It can be 
calculated at any level in the MedDRA hierarchy. How will the index change with level of hierarchy 
chosen? We have the following general propositions. Firstly, as you go from preferred term (PT) to 
HLGT, we expect the AdX value to decline. The second proposition is that the rank of treatment in terms 
of AdX will remain the same across different levels. However, significance of differences in AdX values 
may change. So the third proposition is: if a difference in AdX values is significant at a higher MedDRA 
level, we expect it to remain significant at a lower level as well. Converse may not hold. It is possible to 
get significance at lower level while failing to get significance at higher level. Fourth and the last 
proposition is that if a treatment difference fails to attain significance at lower hierarchy level, it will 
continue to be so at higher level. Here also converse may not hold true. We illustrate these ideas with data 
on the BI trial. Figure 3 shows AdX values by treatment, background medication (Met or METSU) and 
MedDRA level (PT, HLT and HLGT).  
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Each of six lines in Figure 3 represents AdX values for three treatments. Solid line is for background 
therapy ‘Metformin’ and dotted one for background therapy ‘Metformin + SU’. As we go to higher level 
of MedDRA hierarchy, AdX value reduces (proposition one). This is because count of distinct types 
reduces. [Range for counts between different treatment groups: PT level (150,200), HLT level (120,130), 
HLGT level (70, 80)].  Further, three lines for each background therapy are roughly parallel implying 
ranking remains unchanged irrespective of hierarchy level (proposition two).  Table 11 is useful as 
illustration of propositions three and four. It gives p-values for differences (Active- placebo) for two 
background therapy groups.  
Table 11:Treatment comparison by MedDRA levels 
(p-values) 
 
Metformin Met + SU 
1 2 3 4 5 
MedDRA 
level 
10mg-
Placebo 
25mg-
Placebo 
10mg-
Placebo 
25mg-
Placebo 
PT 0.042 0.013 0.500 0.039 
HLT 0.000 0.002 0.457 0.050 
HLGT 0.016 0.022 0.258 0.232 
Data Source: NCT01159600; Sponsor Name: Boehringer 
Ingelheim (BI); Indication: Diabetes Mellitus Type II. 
 
Consider column 2. Here p-value for HLGT is small. Proposition three predicts that difference should 
be significant at HLT and PT as well. This is true. Same result holds for column 3. Consider column 4. P-
value for PT is large. Proposition four predicts that p-values for HLT and HLGT should also be large. This 
is true.  Column 5 demonstrates that converse of proposition three is not necessarily true. The difference is 
significant at PT and HLT level but not at HLGT level.  
4.9 Using AdX in benefit risk analysis:  
 
Drug approval typically requires a confirmatory proof of efficacy followed by a benefit-risk 
assessment. The latter is another hot topic in the clinical trial domain.  It is felt that ‘regulators need to 
refine their methods of assessing benefit–risk balances and switch from ‘implicit’ to ‘explicit’ decision 
making’ 15. Benefit-risk ratio (BRR) is discussed extensively in literature16. Several measures of BRR 
have been proposed
17,18
. But there is no unanimity. The key problem appears to be the quantification of 
risk. Broad summary terms such as ‘generally safe’ or ‘well tolerated’ are commonly used.    These terms 
have been criticized in literature
3
. Phrases such as ‘favourable risk- benefit profile’, ‘manageable toxicity’ 
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may be adequate to describe the safety profile verbally but not so for calculating the BRR.  Analysis often 
begins with the application of statistical methods to an individual efficacy end point or an adverse event 
type. However, overall conclusion is only a judgmental statement. This is because of difficulty in 
aggregating component results.  
Our approach is to avoid these pitfalls.  We can use a primary efficacy end point or a suitable 
composite of multiple efficacy end points to represent the benefit.  AdX provides a measure of risk. The 
Ratio of Efficacy to Adversity (REAd) can be used as the BRR of a treatment (REAd= average 
efficacy/AdX). For a comparison of two treatments, the ratio of the two REAds can be calculated. This 
ratio can be called the Relative REAd (Re-REAd). If two treatments T1 and T2 have similar efficacy, but 
T1 has a smaller AdX (safer) than T2, then the REAd value of T1 will be higher. We illustrate these ideas 
by applying them to the EL trial. 
Here is the conclusion from the  sponsors of the EL trial: ‘Patients on GT arm had a statistically 
significant improvement in TtDPD with an approximate 50% relative increased probability of a patient 
being documented progression free at 6 months ... This was accompanied with a statistically significant 
improvement in PFS and overall tumour response rate for the patients on GT arm. ... In addition, the 
patients on the GT arm had a significant improvement in overall valuation of life at cycles 5 and 6 
compared with baseline. Overall, GT combination chemotherapy is an effective and well tolerated 
chemotherapy regimen, with an expected and manageable toxicity. This favourable benefit risk profile 
supports the use of Gemcitabine + Paclitaxel combination therapy in patients with metastatic breast 
cancer’ (CSR p. 6). 
Treatments cannot be compared only in terms of efficacy unless proper discounting for safety 
performance is applied [1]. The sponsors have argued that ‘No new trends or safety concerns were 
observed following examination of the adverse events reported during this study’. In this sense, safety 
profiles of two arms are deemed to be similar. Hence, efficacy of GT relative to T (control) essentially 
represents the benefit risk balance. The conclusion that safety profiles are similar appears to be based on 
the rates of occurrence of the events of special interest. It does not seem to consider the entire gamut of 
adverse events. If the overall safety profiles of the two arms are different, then we must take cognizance of 
differences in safety and discount benefit accordingly.   
Table 12 shows the efficacy and REAd values by treatment. The conclusion based on Re-REAd is in 
agreement with that of the sponsors, viz. the performance of GT is slightly better than that of T. Thus, in 
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this case, the proposed BRR measure confirms the conclusions in the CSR. Of course statistical testing of 
the hypothesis that two treatments have comparable BRR (Re-REAd=1) has to be addressed. One possible 
solution is using boot strap confidence interval for Re-REAd.  
Table 12: Calculation of REAd and Re-REAd(EL) 
 
Efficacy  Safety  
 
Median PFS (months) AdX REAd* 
GT 5.3 3.64 1.46 
T 3.5 3.48 1.01 
Re-REAd(GT/T)**          1.45 
*REAd: Ratio of Efficacy and AdX , ** Re-REAd: Relative REAd 
Data Source: NCT00006459; Sponsor Name: Eli Lilly; Indication: Breast Cancer.  
† 
Treatment: GT= Gemcitabine + Paclitaxel; T= Paclitaxel. 
 
The next illustration reveals some finer points of treatment comparison for the BI trial, unnoticed in 
the CSR. The results of this analysis are shown in Table 13. 
Table 13: Benefit Risk Analysis for Two Sub-studies in BI Trial 
Sub Study Row  
number 
Statistic Treatment Arm 
10 mg 25mg Placebo 
Metformin 1 Benefit: Primary Efficacy: MeanCFB HbA1C -0.72 -0.75 -0.13 
2 Risk: AdX 4.64 4.68 4.49 
3 REAd 0.155 0.160 0.029 
4 Re-REAd (Empagliflozin/Placebo) 5.36 5.54  
Metformin + SU 5 Benefit:Primary Efficacy: MeanCFB HbA1C -0.80 -0.77 -0.18 
6 Risk: AdX 4.35 4.17 4.35 
7 REAd 0.184 0.185 0.041 
8 Re-REAd(Empagliflozin/Placebo) 4.44 4.46 
 
Data Source: NCT01159600; Sponsor Name: Boehringer Ingelheim (BI); Indication: Diabetes Mellitus 
Type II. 
 
For each sub-study and treatment arm, Table 13 shows the efficacy (borrowed from the CSR), risk 
(AdX), benefit-risk ratio (REAd) and Re-REAd of the active treatment Vs the placebo. In the metformine 
sub-study, we observe that both the treatment arms show substantially larger efficacy than the placebo. On 
the other hand the differences in risk are much smaller. Hence our index for benefit-risk balance viz. 
REAd is quite high for both active treatment arms. The story with Metformin + SU is essentially the same. 
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In conclusion we can say that irrespective of the background medication, each active treatment arm 
achieves better performance than the placebo (background medication alone).  
The last point is comparison of sub-studies. Here we are going beyond the report of the trial. Naturally 
CSR is silent about this. We attempt to address the following question: How does the performance of an 
active treatment compare across background medication? The efficacy value for each treatment arm is 
slightly higher in the Metformine+SU sub-study than corresponding value in the Metformine sub-study. 
The AdX value for each treatment arm is slightly lower in the Metformine+SU sub-study than 
corresponding value in the Metformine sub-study. Therefore the Metformine +SU sub-study shows higher 
REAd values for each treatment arm. It is tempting to conclude that active treatment performs better with 
Metformine + SU background therapy. The unexpected twist comes next. 
The above conclusion may be challenged using the argument that the placebos in two sub-studies are 
not identical. Perhaps we should rephrase our main question. Is the improvement shown by active 
treatment over the placebo similar for two background medications? The ratio Re-REAd (active /placebo) 
helps in answering this question. These Re-REAd values are shown in rows 4 and 8 of Table 13. The Re-
REAd values are higher when Metformine is the background medication compared with corresponding 
values, when Metformine+SU as the background medication. Thus, each dose of active treatment provides 
a better advantage over the placebo when Metformine is the back ground therapy than when Metformine+ 
SU is the background therapy.  Such analysis became possible because of quantification of risk (AdX).  
 
5. Discussion 
This paper proposes a new index to summarise safety profile of a treatment in a clinical trial. This 
index is not intended to replace present method of focussing on events of special interest which are 
clinically important. If a treatment is judged to be unsafe and unacceptable based on rates of occurrence of 
these events, other adverse events may not play a role in decision making. Otherwise AdX is thought to be 
a more effective tool than present method of reporting just counts and percentages.  The paper 
demonstrates how hypothesis of comparable safety profile can be statistically tested. It further shows use 
of this index in subgroup analysis and benefit risk balance assessment. Such analysis can lead to findings/ 
features likely to be missed in conventional analysis. 
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